GEN-1 in Combination with Neoadjuvant Chemotherapy for Patients with Advanced Epithelial Ovarian Cancer: A Phase I Dose-escalation Study.

Premal H ThakerWilliam H BradleyCharles A LeathCamille Gunderson JacksonNicholas BorysKhursheed AnwerLauren MussoJunko MatsuzakiWiam BsharaKunle OdunsiRonald D Alvarez

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

Adding GEN-1 to standard NACT is safe, appears active, and has an impact on the tumor microenvironment.

Keyphrases

neoadjuvant chemotherapy
locally advanced
lymph node
sentinel lymph node
squamous cell carcinoma
open label
clinical trial
radiation therapy